Recent efforts to develop tumor-targeted photodynamic therapy (PDT) photosensitizers (PSs) have greatly advanced the potential of PDT in cancer therapy, although complete eradication of tumor cells by PDT alone remains challenging. As a way to improve PDT efficacy, we report a new combinatory PDT therapy technique that specifically targets multilayers of cells. Simply mixing different PDT PSs, even those that target distinct receptors (this may still lead to similar cell-killing pathways), may not achieve ideal therapeutic outcomes. Instead, significantly improved outcomes likely require synergistic therapies that target various cellular pathways. In this study, we target two proteins upregulated in cancers: the cannabinoid CB2 receptor (CB 2 R, a G-protein coupled receptor) and translocator protein (TSPO, a mitochondria membrane receptor). We found that the CB 2 R-targeted PS, IR700DX-mbc94, triggered necrotic cell death upon light irradiation, whereas PDT with the TSPO-targeted IR700DX-6T agent led to apoptotic cell death. Both PSs significantly inhibited tumor growth in vivo in a target-specific manner. As expected, the combined CB 2 R-and TSPO-PDT resulted in enhanced cell killing efficacy and tumor inhibition with lower drug dose. The median survival time of animals with multilayer PDT treatment was extended by as much as 2.8-fold over single PDT treatment. Overall, multilayer PDT provides new opportunities to treat cancers with high efficacy and low side effects.
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Introduction
Photodynamic therapy (PDT) offers a minimally invasive, effective and highly controllable therapeutic strategy, and has become popular as an alternative or additional approach to conventional cancer treatments, such as chemotherapy and surgery [1, 2] . During the process of PDT, a light-sensitive photosensitizer (PS) is activated by light irradiation at a specific wavelength to produce reactive oxygen species (ROS), such as singlet oxygen and free radical, which consequently lead to cell death [3] . PDT has been clinically approved to treat several types of cancers, such as esophageal and non-small cell lung cancer, as well as precancerous changes of Barrett's esophagus and skin (actinic keratosis). Moreover, many clinical trials are currently
